Company Analysis

Grace Therapeutics, Inc. (GRCE)

Nasdaq: GRCE · Pharmaceutical Preparations · Princeton, NJ · filing with the SEC since 2008
Grade5.0
◀ Past 4.6● Present 5.3▶ Future 4.9
6 est.

Who runs Grace Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Kohli Prashant
Chief Executive Officer. First filing Sep 2022, latest Sep 10, 2026, 1 filing in all.
Officers reporting now
5
of 8 people with a filing in the last fifteen months
Directors reporting now
3
19 people on the record since 2017
Officerssales are open-market, Nov 5, 2025 to Nov 5, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Kottayil GeorgeCOO, USNov 2021Sep 21, 2026none
Kohli PrashantChief Executive OfficerSep 2022Sep 10, 2026none
Macdonald R. LochChief Medical OfficerMay 2023Sep 1, 2026none
Delaversano Robert JPrincipal Financial OfficerJan 2024Sep 1, 2026none
Kumar AmreshVP Program ManagementMay 2023Sep 1, 2026none
Directorssales are open-market, Nov 5, 2025 to Nov 5, 2026
NameRoleFirst filingLatest filingSales, 12 months
Davis A BriandirectorOct 2023Sep 21, 2026none
Kavuru VimaldirectorSep 2021Sep 21, 2026none
Neugeboren EdwarddirectorOct 2023Sep 21, 2026none
Owners of more than 10% of a classsales are open-market, Nov 5, 2025 to Nov 5, 2026
NameRoleFirst filingLatest filingSales, 12 months
Opaleye Management Inc.10% ownerAug 2026Nov 5, 2026none
Earlier names on the record15, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton GRCE · research, not advice